Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPrime Therapeutics ApoC3 Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentPrime TherapeuticsPolicy N/A

    ApoC3 Targeting Agents Prior Authorization with Quantity Limit Program Summary

    Customize your policy alerts

    Sign up for all prime_therapeutics policy alerts

    Know when prime_therapeutics releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and quantity-limit approval for Tryngolza (olezarsen) and Redemplo (plozasiran) for commercial Boeing members. It establishes initial-therapy, renewal, clinical-criteria, and quantity-limit requirements.

    Policy Summary
    PayerPrime Therapeutics
    PolicyApoC3 Targeting Agents Prior Authorization with Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage change
    Effective DateNov 15, 2026
    Next Review DateN/A
    Key ActionSubmit documentation of an eligible diagnosis or supported indication, applicable age support, specialist involvement, and absence of FDA-labeled contraindications for initial approval.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthsInitial and renewal authorization period
    1 per 84 daysRedemplo quantity limit
    1 per 28 daysTryngolza quantity limit
    <20 g/dayLow-fat diet requirement for FCS

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    3 priorFCS triglyceride measurements without genetic confirmation

    Coverage Criteria

    Initial Therapy

    Covered when ALL of the following are met:

    ALL of the following

    • ONE of the following diagnoses

      • Familial chylomicronemia syndrome (FCS)

        • ONE of the following confirms FCS

          • Genetic confirmation of bi-allelic pathogenic variants in affected genes (e.g., LPL, ApoA5, ApoC2, LMF1, GPIHBP1, G3PDH1).
          • ALL of the following

            • Fasting triglyceride (TG) levels greater than 880 mg/dL for 3 prior measurements.

              Chart notes required.

            • Secondary causes of hypertriglyceridemia have been ruled out (e.g., alcohol use, chronic kidney disease, hypothyroidism, uncontrolled diabetes, or medications such as atypical antipsychotics, beta-blockers, corticosteroids, or oral estrogens).
            • History of pancreatitis or unexplained recurrent abdominal pain.
            • No response to conventional lipid-lowering therapies (e.g., fibrates, omega-3 fatty acids, statins, niacin, ezetimibe, or PCSK9 inhibitors).TG decrease < 20%
        • The patient will use the requested agent in combination with a low-fat diet.< 20 g of fat per day
      • Severe hypertriglyceridemia (sHTG)

        • The requested agent is Tryngolza.
        • The patient has a fasting TG level equal to or greater than 500 mg/dL.≥ 500 mg/dL
        • The patient is currently on lipid-lowering therapy and has been stabilized on therapy for at least 4 weeks.≥ 4 weeks
        • The patient has a hemoglobin A1c (HbA1c) of less than 9.5%.< 9.5%
        • The patient has an estimated GFR (eGFR) of at least 30 mL/min/1.73 m².≥ 30 mL/min/1.73 m²
      • Another FDA-labeled indication for the requested agent and route of administration.
      • An indication that is supported in compendia for the requested agent and route of administration.

        Compendia allowed: AHFS, or DrugDex 1, 2a, or 2b level of evidence.

    • ONE of the following age criteria

      • The patient's age is within FDA labeling for the requested indication for the requested agent.
      • There is support for using the requested agent for the patient's age for the requested indication.
    • The prescriber is a specialist in the area of the patient's diagnosis (e.g., cardiologist, endocrinologist, gastroenterologist, or lipidologist), or the prescriber has consulted with a specialist in the area of the patient's diagnosis.
    • The patient does NOT have any FDA-labeled contraindications to the requested agent.

    Continuation Therapy

    Covered when ALL of the following are met:

    ALL of the following

    • The patient has been previously approved for the requested agent through the plan's Prior Authorization process.

      Patients not previously approved for the requested agent will require initial evaluation review.

    • The patient has had clinical benefit with the requested agent.
    • If the patient has a diagnosis of FCS

      • The patient will use the requested agent in combination with a low-fat diet.< 20 g of fat per day
      • The patient does not have a diagnosis of FCS.

    Quantity-Limit Exception

    The quantity limit exception will be approved when ONE of the following is met:

    ANY of the following

    • The requested quantity (dose) does NOT exceed the program quantity limit.
    • The requested quantity exceeds the program quantity limit AND ONE of the following exceptions applies

      • Exception A

        • The requested agent does NOT have a maximum FDA-labeled dose for the requested indication.
        • There is support for therapy with a higher dose for the requested indication.
      • Exception B

    Clinical Thresholds

    FCS fasting triglycerides
    Threshold> 880 mg/dL
    Required measurements3 prior fasting triglyceride measurements
    DocumentationChart notes are required for the three measurements
    Severe hypertriglyceridemia fasting triglycerides
    Threshold>= 500 mg/dL
    MeasurementFasting triglyceride level
    Applies toSevere hypertriglyceridemia criteria

    Authorization and Documentation Requirements

    Prior Authorization

    Initial Prior Authorization

    Obtain initial prior authorization before dispensing the requested ApoC3-targeting agent. Approval requires a qualifying diagnosis or supported indication, applicable age support, specialist involvement or specialist consultation, and no FDA-labeled contraindication.

    • For FCS, submit the required diagnostic and clinical documentation, including the applicable genetic or non-genetic criteria.
    • For severe hypertriglyceridemia, the requested agent must be Tryngolza and all specified clinical criteria must be met.
    • Other FDA-labeled indications or compendia-supported indications must be supported for the requested agent and route; allowed compendia include AHFS and DrugDex evidence levels 1, 2a, or 2b.
    • When the indication is FDA labeled, document that the patient is within the FDA-labeled age range or provide support for use at the patient's age.
    • Initial approvals are granted for 12 months; refer to the quantity-limit criteria when applicable.
    Prior Authorization

    Renewal Prior Authorization

    Policy Background

    This policy addresses ApoC3-targeting therapies, including Tryngolza (olezarsen) and Redemplo (plozasiran), for familial chylomicronemia syndrome (FCS) and other eligible indications. FCS may be established through genetic confirmation of biallelic pathogenic variants or through specified clinical and laboratory findings, including severe fasting hypertriglyceridemia, exclusion of secondary causes, a history of pancreatitis or unexplained recurrent abdominal pain, and inadequate response to conventional lipid-lowering therapy. Tryngolza is also considered for severe hypertriglyceridemia when the required triglyceride, treatment-stabilization, glycemic-control, and renal-function criteria are met.

    Key Definitions

    FCS
    DefinitionFamilial chylomicronemia syndrome
    Genetic pathwayBiallelic pathogenic variants in affected genes, such as LPL, ApoA5, ApoC2, LMF1, GPIHBP1, or G3PDH1
    Clinical pathwayFasting TG > 880 mg/dL for 3 prior measurements, secondary causes ruled out, pancreatitis or unexplained recurrent abdominal pain, and no response to conventional lipid-lowering therapy
    sHTG
    DefinitionSevere hypertriglyceridemia (sHTG)
    Triglyceride requirementFasting TG >= 500 mg/dL
    Additional requirements

    Initial Therapy Criteria

    Initial Therapy Criteria

    Target agent(s) will be approved when ALL of the following are met.

    Initial therapy requirements

    • Eligible diagnosis or supported indication: The patient has FCS, severe hypertriglyceridemia meeting the Tryngolza-specific criteria, another FDA-labeled indication for the requested agent and route, or a compendia-supported indication for the requested agent and route.
    • Age support when an FDA-labeled indication is used: The patient's age is within FDA labeling for the requested indication, or there is support for using the requested agent for the patient's age and indication.
    • Specialist involvement and safety

      • The prescriber is a specialist in the area of the patient's diagnosis or has consulted with a specialist.

    Continuation Criteria

    Continuation Therapy Criteria

    Target agent(s) will be approved when ALL of the following are met.

    Renewal requirements

    • The patient was previously approved for the requested agent through the plan's prior authorization process.
    • The patient has had clinical benefit with the requested agent.
    • If the patient has FCS, the requested agent will be used in combination with a low-fat diet.<20 g of fat per day
    • The prescriber is a specialist in the area of the patient's diagnosis or has consulted with a specialist.

    Required Prior Therapy

    StepRequirementExamplesFailure definition
    1For FCS supported by clinical and laboratory findings, prior treatment with conventional lipid-lowering therapy is required.Fibrates; omega-3 fatty acids; statins; niacin; ezetimibe; or PCSK9 inhibitors.No response, defined as a triglyceride decrease of less than 20%.

    Quantity Limits

    Redemplo quantity limit
    AgentRedemplo (plozasiran sodium) 25 mg/0.5 mL
    Quantity limit1
    Day supply84 days
    Tryngolza 50 mg/0.8 mL quantity limit
    AgentTryngolza (olezarsen sodium) 50 mg/0.8 mL
    Quantity limit1
    Day supply28 days
    Policy Summary
    PayerPrime Therapeutics
    PolicyApoC3 Targeting Agents Prior Authorization with Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage change
    Effective DateNov 15, 2026
    Next Review DateN/A
    Key ActionSubmit documentation of an eligible diagnosis or supported indication, applicable age support, specialist involvement, and absence of FDA-labeled contraindications for initial approval.
    SourceLink
    On This Page
    Coverage CriteriaClinical ThresholdsAuthorization and Documentation RequirementsPolicy BackgroundKey DefinitionsInitial Therapy CriteriaContinuation CriteriaRequired Prior TherapyQuantity Limits
    The prescriber is a specialist in the area of the patient's diagnosis (e.g., cardiologist, endocrinologist, gastroenterologist, or lipidologist), or the prescriber has consulted with a specialist in the area of the patient's diagnosis.
  1. The patient does NOT have any FDA-labeled contraindications to the requested agent.
  2. The requested quantity (dose) does NOT exceed the maximum FDA-labeled dose for the requested indication.
  3. There is support for why the requested quantity (dose) cannot be achieved with a lower quantity of a higher strength that does NOT exceed the program quantity limit.
  4. Exception C

    • The requested quantity (dose) exceeds the maximum FDA-labeled dose for the requested indication.
    • There is support for therapy with a higher dose for the requested indication.
  5. HbA1c threshold
    Threshold< 9.5%
    TestHemoglobin A1c (HbA1c)
    Applies toSevere hypertriglyceridemia criteria
    eGFR threshold
    Threshold>= 30 mL/min/1.73 m²
    TestEstimated glomerular filtration rate (eGFR)
    Applies toSevere hypertriglyceridemia criteria
    FCS low-fat diet requirement
    Diet requirement< 20 g of fat per day
    Applies toUse of the requested agent for FCS
    TimingRequired for initial and renewal approval when the diagnosis is FCS
    Response to conventional lipid-lowering therapy
    No-response thresholdTriglyceride decrease < 20%
    TherapyConventional lipid-lowering therapy
    ExamplesFibrates, omega-3 fatty acids, statins, niacin, ezetimibe, and PCSK9 inhibitors

    Submit renewal prior authorization documentation before the current approval expires. Renewal requires prior plan approval and documented clinical benefit with the requested agent.

    • If the patient has FCS, document continued use with a low-fat diet of less than 20 g of fat per day.
    • Renewal also requires specialist prescribing or specialist consultation and absence of FDA-labeled contraindications.
    • Patients without prior approval through the plan's prior authorization process require initial evaluation review.
    • Renewal approvals are granted for 12 months; refer to the quantity-limit criteria when applicable.
    Prior Authorization

    Quantity-Limit Authorization

    Obtain quantity-limit authorization when the requested dose or quantity exceeds the program limit. The standard quantity is approvable when it does not exceed the applicable program limit.

    • A higher quantity requires documentation supporting one of the permitted higher-dose exceptions.
    • The exception must address the agent's maximum FDA-labeled dose, whether a higher dose is supported for the indication, and why a lower quantity of a higher strength cannot achieve the requested dose when applicable.
    • Quantity-limit approvals are granted for 12 months.
    Documentation Required

    Failure of Conventional Lipid-Lowering Therapy

    Document failure of conventional lipid-lowering therapy when requesting treatment for FCS. The record must show inadequate response despite appropriate conventional therapy.

    • Document a triglyceride decrease of less than 20% with conventional lipid-lowering therapies.
    • Relevant therapies may include fibrates, omega-3 fatty acids, statins, niacin, ezetimibe, or PCSK9 inhibitors.
    • Include treatment history and supporting chart notes.
    Documentation Required

    Clinical Records for Diagnosis and Eligibility

    Submit clinical records establishing the diagnosis and eligibility for the requested agent. For FCS, provide either genetic confirmation of bi-allelic pathogenic variants in an affected gene or the required non-genetic clinical evidence.

    • Genetic evidence may include pathogenic bi-allelic variants in genes such as LPL, ApoA5, ApoC2, LMF1, GPIHBP1, or G3PDH1.
    • Non-genetic FCS documentation must include three prior fasting triglyceride measurements above 880 mg/dL, exclusion of secondary causes, a history of pancreatitis or unexplained recurrent abdominal pain, and inadequate response to conventional lipid-lowering therapy.
    • Document use of the requested agent with a low-fat diet of less than 20 g of fat per day when FCS is the diagnosis.
    Documentation Required

    Severe Hypertriglyceridemia Laboratory Documentation

    For severe hypertriglyceridemia eligibility, submit laboratory and treatment records showing the required triglyceride threshold and stabilized lipid-lowering therapy. The requested agent must be Tryngolza for this indication.

    • Document a fasting triglyceride level of at least 500 mg/dL.
    • Document current lipid-lowering therapy and stabilization on that therapy for at least 4 weeks.
    • Also submit the required HbA1c below 9.5% and eGFR of at least 30 mL/min/1.73 m².

    Unsupported block type: documentation

    Unsupported block type: documentation

    Denial Risk

    Failure to Meet Core Eligibility Requirements

    Authorization may be denied when core eligibility requirements are not established. This includes failure to document a qualifying diagnosis or supported indication, applicable age eligibility, specialist involvement, or the absence of FDA-labeled contraindications.

    • Deny when the requested agent or route lacks an FDA-labeled or compendia-supported indication.
    • Deny when required age support is absent for an FDA-labeled indication.
    • Deny when specialist prescribing or consultation is not documented, or when an FDA-labeled contraindication is present.
    Denial Risk

    FCS Criteria Not Established

    FCS authorization may be denied when the required FCS criteria are not established. The record must support the fasting triglyceride, secondary-cause exclusion, clinical-history, and treatment-response requirements when genetic confirmation is not provided.

    • Deny when three prior fasting triglyceride measurements are not greater than 880 mg/dL or are not supported by chart notes.
    • Deny when secondary causes of hypertriglyceridemia have not been ruled out.
    • Deny when there is no history of pancreatitis or unexplained recurrent abdominal pain, or when failure of conventional therapy is not demonstrated by a triglyceride decrease of less than 20%.
    Denial Risk

    Severe Hypertriglyceridemia Criteria Not Met

    Authorization for severe hypertriglyceridemia may be denied when the required agent selection, laboratory threshold, or related clinical criteria are not met. This indication requires Tryngolza and all specified criteria.

    • Deny when the requested agent is not Tryngolza, when fasting triglycerides are below 500 mg/dL, or when lipid-lowering therapy has not been stabilized for at least 4 weeks.
    • Deny when HbA1c is 9.5% or higher or eGFR is below 30 mL/min/1.73 m².
    • Deny when the required current lipid-lowering therapy or supporting laboratory documentation is absent.
    Denial Risk

    Renewal Requirements Not Met

    Renewal may be denied when the patient was not previously approved through the plan's prior authorization process or when clinical benefit with the requested agent is not documented.

    • Patients without prior plan approval must be submitted for initial evaluation review.
    • For FCS, deny renewal when continued use with a low-fat diet of less than 20 g of fat per day is not documented.
    • Deny when required specialist involvement or consultation is not documented or when an FDA-labeled contraindication is present.
    Denial Risk

    Unsupported Quantity-Limit Exception

    A quantity-limit exception may be denied when the requested dose exceeds the program limit without adequate support. The request must satisfy one of the approved higher-dose exception pathways.

    • Deny when there is no support for therapy with the requested higher dose.
    • Deny when the request does not address the maximum FDA-labeled dose for the indication when applicable.
    • Deny when a lower quantity of a higher strength within the program limit could achieve the dose and no rationale is provided, or when the requested dose exceeds the maximum FDA-labeled dose without supporting evidence.
    The requested agent is Tryngolza; lipid-lowering therapy has been stabilized for at least 4 weeks; HbA1c is < 9.5%; and eGFR is >= 30 mL/min/1.73 m²
  6. The patient does not have any FDA-labeled contraindication to the requested agent.
  7. The patient does not have any FDA-labeled contraindication to the requested agent.
    Tryngolza 80 mg/0.8 mL quantity limit
    AgentTryngolza (olezarsen sodium) 80 mg/0.8 mL
    Quantity limit1
    Day supply28 days